Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA.
Aged
Antiviral Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ prevention & control
Dietary Supplements
Female
Hepacivirus
Hepatitis C
/ blood
Humans
Incidence
Liver Neoplasms
/ prevention & control
Male
Middle Aged
Multivariate Analysis
Retrospective Studies
Sustained Virologic Response
Zinc
/ administration & dosage
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
14
06
2021
received:
08
03
2021
accepted:
21
06
2021
pubmed:
10
11
2021
medline:
22
1
2022
entrez:
9
11
2021
Statut:
ppublish
Résumé
We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between zinc intake and HCC development (study 2) in patients with hepatitis C virus (HCV) eradicated by direct-acting antivirals (DAAs). A total of 599 sustained virological response (SVR) patients treated with DAAs without a history of HCC were retrospectively analyzed in this study. Eighty patients received supplemental zinc (Zn treatment group), and 519 patients did not receive zinc (no Zn treatment group). In study 1, the cumulative incidence rate of HCC was compared between the Zn treatment group and the no Zn treatment group. In study 2, the risk factors for HCC development were examined in the no Zn treatment group. In study 1, in the Zn treatment group, HCC did not develop during follow-up, and the cumulative risk of HCC was significantly lower in the Zn treatment group than in the no Zn treatment group (P = 0.048). In study 2, the 1-year and 3-year cumulative incidence rates of HCC were 1.8% and 5.6%, respectively. The risk factors for HCC identified by multivariate analysis were male sex, cirrhosis, low platelet count before treatment, and low serum zinc concentration 12 weeks after the end of DAA therapy. Conclusion: The Zn concentration is related to HCC development in patients with HCV eradicated by DAA therapy. Oral zinc supplementation is recommended as a means of suppressing HCC development in patients who have achieved SVR.
Identifiants
pubmed: 34752016
doi: 10.1002/hep4.1782
pmc: PMC8631098
doi:
Substances chimiques
Antiviral Agents
0
Zinc
J41CSQ7QDS
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2001-2008Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Free Radic Biol Med. 2003 Apr 1;34(7):908-10
pubmed: 12654479
Am J Clin Nutr. 1970 Feb;23(2):170-7
pubmed: 5415563
J Hepatol. 2014 Nov;61(1 Suppl):S79-90
pubmed: 25443348
Hepatol Res. 2007 Jun;37(6):405-9
pubmed: 17539814
Am J Clin Pathol. 1965 Oct;44(4):426-35
pubmed: 5839914
Hepatology. 2020 Jan;71(1):44-55
pubmed: 31222774
Hepatol Res. 2019 May;49(5):570-578
pubmed: 30623521
Free Radic Res. 2004 Jun;38(6):573-80
pubmed: 15346648
N Engl J Med. 1956 Aug 30;255(9):403-8
pubmed: 13358854
Lancet. 1984 Sep 1;2(8401):493-5
pubmed: 6147551
Nutr J. 2013 Jun 06;12:74
pubmed: 23742732
Ann Intern Med. 2017 May 2;166(9):637-648
pubmed: 28319996
J Nutr. 2001 Dec;131(12):3208-11
pubmed: 11739867
Cancer Biol Ther. 2014 Apr;15(4):353-60
pubmed: 24448510
Nutrition. 2014 Nov-Dec;30(11-12):1409-14
pubmed: 25280421
Nutrients. 2018 Dec 10;10(12):
pubmed: 30544767
Cancers (Basel). 2020 May 26;12(6):
pubmed: 32466400
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
Gastroenterology. 2014 May;146(5):1176-92
pubmed: 24631495
Commun Biol. 2018 Aug 22;1:113
pubmed: 30271993